Thomas M. Snyder, PhD

VP, Research
Adaptive Biotechnologies
Seattle, WA, United States

Thomas Snyder, VP of Research at Adaptive Biotechnologies, is the scientific lead for the TCR-Antigen Map program, a collaboration with Microsoft to map T-cell receptors in an immune repertoire to specific antigens and disease endpoints in order to interpret an individual's immune history. The Antigen Map team's research led to T-Detect COVID, a first-of-its-kind T-cell based test to measure recent or past infection by SARS-CoV-2 that received emergency use authorization from the FDA, with several other tests now in development.

Before his current role, Thomas was Head of Computational Biology at Verily Life Sciences overseeing a set of systems biology, immunology, and image machine learning projects. Prior to that, Thomas was Chief Scientist at ImmuMetrix, LLC where he developed a new platform for organ transplant management connected to a methodology he invented during post-doctoral research at Stanford University/HHMI (Bioengineering).

Adaptive Biotechnologies (Employee, Shareholder)

Presentation(s):

• 126 - Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection and Vaccination

  On Demand

• 144 - Clinical Validation and Performance of a T-cell Immunosequencing Assay to Identify Past SARS-CoV-2 Infection

  On Demand

• LB17 - Immunosequencing of the T-Cell Receptor Repertoire Reveals Signatures Specific for Diagnosis and Characterization of Early Lyme Disease

  Saturday, October 2, 2021
  1:15 PM - 3:00 PM EDT